Virtual screening of flavonoids as potential RIPK1 inhibitors for neurodegeneration therapy

被引:3
|
作者
Bepari, Asim Kumar [1 ]
Shatabda, Swakkhar [2 ]
Reza, Hasan Mahmud [1 ]
机构
[1] North South Univ, Dept Pharmaceut Sci, Dhaka, Bangladesh
[2] United Int Univ, Dept Comp Sci & Engn, Dhaka, Bangladesh
来源
PEERJ | 2024年 / 12卷
关键词
Bioinformatics; Drug discovery; Docking; Molecular dynamics; Simulation; Kinase; Gromacs; AutoDock vina; Computational; Flavonoid; SOFTWARE NEWS; PROTEIN;
D O I
10.7717/peerj.16762
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Global prevalence of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease is increasing gradually, whereas approvals of successful therapeutics for central nervous system disorders are inadequate. Accumulating evidence suggests pivotal roles of the receptor-interacting serine/ threonine-protein kinase 1 (RIPK1) in modulating neuroinflammation and necroptosis. Discoveries of potent small molecule inhibitors for RIPK1 with favorable pharmacokinetic properties could thus address the unmet medical needs in treating neurodegeneration. Methods: In a structure-based virtual screening, we performed site-specific molecular docking of 4,858 flavonoids against the kinase domain of RIPK1 using AutoDock Vina. We predicted physicochemical descriptors of the top ligands using the SwissADME webserver. Binding interactions of the best ligands and the reference ligand L8D were validated using replicated 500-ns Gromacs molecular dynamics simulations and free energy calculations. Results: From Vina docking, we shortlisted the top 20 flavonoids with the highest binding affinities, ranging from -11.7 to -10.6 kcal/mol. Pharmacokinetic profiling narrowed down the list to three orally bioavailable and blood-brain-barrier penetrant flavonoids: Nitiducarpin, Pinocembrin 7-O-benzoate, and Paratocarpin J. Next, trajectories of molecular dynamics simulations of the top protein-ligand complexes were analyzed for binding interactions. The root-mean-square deviation (RMSD) was 1.191 angstrom (+/- 0.498 angstrom), 1.725 angstrom (+/- 0.828 angstrom), 1.923 angstrom (+/- 0.942 angstrom), 0.972 angstrom (+/- 0.155 angstrom) for Nitiducarpin, Pinocembrin 7-O-benzoate, Paratocarpin J, and L8D, respectively. The radius of gyration (Rg) was 2.034 nm (+/- 0.015 nm), 2.0.39 nm (+/- 0.025 nm), 2.053 nm (+/- 0.021 nm), 2.037 nm (+/- 0.016 nm) for Nitiducarpin, Pinocembrin 7-O-benzoate, Paratocarpin J, and L8D, respectively. The solvent accessible surface area (SASA) was 159.477 nm2 (+/- 3.021 nm2), 159.661 nm2 (+/- 3.707 nm2), 160.755 nm2 (+/- 4.252 nm2), 156.630 nm2 (+/- 3.521 nm2), for Nitiducarpin, Pinocembrin 7-O-benzoate, Paratocarpin J, and L8D complexes, respectively. Therefore, lower RMSD, Rg, and SASA values demonstrated that three ligands. Finally, 2D protein-ligand interaction analysis revealed persistent hydrophobic interactions of Nitiducarpin with the critical residues of RIPK1, including the catalytic triads and the activation loop residues, implicated in the kinase activity and ligand binding. Conclusion: Our target -based virtual screening identified three flavonoids as strong RIPK1 inhibitors, with Nitiducarpin exhibiting the most potent inhibitory potential. Future in vitro and in vivo studies with these ligands could offer new hope for developing effective therapeutics and improving the quality of life for individuals affected by neurodegeneration.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Inhibition of Necroptosis in Acute Pancreatitis: Screening for RIPK1 Inhibitors
    Yao, Jiaqi
    Luo, Yalan
    Liu, Xiaojun
    Wu, Ping
    Wang, Yin
    Liu, Yan
    Chen, Hailong
    Wen, Qingping
    PROCESSES, 2022, 10 (11)
  • [2] Advances in RIPK1 kinase inhibitors
    Chen, Lu
    Zhang, Xiaoqin
    Ou, Yaqing
    Liu, Maoyu
    Yu, Dongke
    Song, Zhiheng
    Niu, Lihong
    Zhang, Lijuan
    Shi, Jianyou
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development
    Bai, Yinliang
    Qiao, Yujun
    Li, Mingming
    Yang, Wenzhen
    Chen, Haile
    Wu, Yanqing
    Zhang, Honghua
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 265
  • [4] RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications
    Ke, Dan
    Zhang, Zhen
    Liu, Jieting
    Chen, Peijian
    Dai, Yucen
    Sun, Xinhai
    Chu, Yanhui
    Li, Luxin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [5] Discovery of potential RIPK1 inhibitors by machine learning and molecular dynamics simulations
    Liu, Ji-xiang
    Na, Ri-song
    Yang, Lian-juan
    Huang, Xu-ri
    Zhao, Xi
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2023, 25 (45) : 31418 - 31430
  • [6] Development of the selective, allosteric RIPK1 kinase inhibitors
    Najjar, Malek
    Suebsuwong, Chalada
    Ray, Soumya
    Cuny, Gregory
    Degterev, Alexei
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [7] Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs
    Martens, Sofie
    Hofmans, Sam
    Declercq, Wim
    Augustyns, Koen
    Vandenabeele, Peter
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2020, 41 (03) : 209 - 224
  • [8] Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors
    S. M. Fayaz
    G. K. Rajanikant
    Journal of Computer-Aided Molecular Design, 2014, 28 : 779 - 794
  • [9] Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors
    Fayaz, S. M.
    Rajanikant, G. K.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2014, 28 (07) : 779 - 794
  • [10] A new perspective on the potential application of RIPK1 in the treatment of sepsis
    Wang, Xuesong
    Chai, Yan
    Guo, Zhe
    Wang, Ziyi
    Liao, Haiyan
    Wang, Ziwen
    Wang, Zhong
    IMMUNOTHERAPY, 2022, 15 (01) : 43 - 56